Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 12/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25767335 | 0.85 | NOS2 (0.40) | USP7DYRK1ANOS3NOS2DHFR | |
| SCHEMBL14997814 | 0.80 | USP7 (0.39) | USP7NOS3NOS2DHFR | |
| SCHEMBL25767334 | 0.74 | NOS2 (0.46) | USP7DYRK1ANOS3NOS2DHFR | |
| SCHEMBL15783283 | 0.74 | USP7 (0.38) | USP7MDM2 | |
| SCHEMBL2220883 | 0.74 | PLAU (0.39) | USP7DYRK1ANOS3NOS2 | |
| SCHEMBL29142223 | 0.73 | DYRK1A (0.38) | DYRK1A | |
| SCHEMBL15662633 | 0.73 | DYRK1A (0.38) | DYRK1A | |
| SCHEMBL23556108 | 0.71 | DYRK1A (0.37) | USP7DYRK1ANOS3NOS2DHFR | |
| SCHEMBL34472031 | 0.71 | FYN (0.38) | USP7DYRK1A | |
| SCHEMBL15781877 | 0.70 | MDM2 (0.42) | MDM2NPC1HTTSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-12 | — | — | US | claimed |
| US-8618302-B2 | Methods and compositions of targeted drug development | Errico, Joseph P. (US) | 2013-12-31 | — | — | US | claimed |
| CN-102811723-A | Methods and compositions for targeted drug development | ERRICO JOSEPH P | 2012-12-05 | — | — | CN | claimed |
| EP-2521553-A2 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2012-11-14 | — | — | EP | claimed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | claimed |
| WO-2011085126-A2 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | ERRICO JOSEPH P | 2011-07-14 | — | — | WO | claimed |
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-12 | — | — | US | disclosed |
| CN-102811723-A | Methods and compositions for targeted drug development | ERRICO JOSEPH P | 2012-12-05 | — | — | CN | disclosed |
| EP-2521553-A2 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011085126-A2 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | ERRICO JOSEPH P | 2011-07-14 | — | — | WO | disclosed |
| WO-2011085126-A2 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | ERRICO JOSEPH P | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | USP7 1582/4885DYRK1A 352/4885NOS3 4749/4885 |
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | USP7 1993/4885DYRK1A 466/4885NOS3 4766/4885 |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB4 | USP7 2017/4885DYRK1A 247/4885NOS3 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.